Biktarvy, PrEP Continue Driving Gilead’s HIV Dominance

 
• By Joseph Haas

HIV remains the main growth franchise for Gilead, despite an anticipated first quarter revenue downturn due to inventory and payer mix. Biktarvy’s launch and growth in PrEP business provide multiple drivers for the franchise.

Pills on Hiv - aids background
The HIV franchise showed strong underlying trends despite a sales decline this past quarter

More from Strategy

More from Business